{"product_id":"biomarin-bcg-matrix","title":"BioMarin Pharmaceutical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about BioMarin Pharmaceutical's product portfolio performance? This glimpse into their BCG Matrix reveals which therapies are driving growth and which might need a strategic rethink. Understand their current market standing and unlock the potential for future success.\u003c\/p\u003e\n\u003cp\u003eDon't miss out on the full strategic picture! Purchase the complete BioMarin Pharmaceutical BCG Matrix to gain detailed quadrant placements, actionable insights into their Stars, Cash Cows, Dogs, and Question Marks, and a clear roadmap for optimizing their product pipeline and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOXZOGO (Vosoritide) for Achondroplasia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVOXZOGO is a star performer for BioMarin, showcasing impressive growth. In 2024, it generated $735 million in global revenue, a substantial 56% jump from the previous year.\u003c\/p\u003e\n\u003cp\u003eThe momentum for VOXZOGO is projected to continue. For 2025, BioMarin anticipates the drug to contribute between $900 million and $950 million to its overall revenue, highlighting its importance as a key growth driver.\u003c\/p\u003e\n\u003cp\u003eThis robust demand is driven by increasing patient uptake across all markets, with a particular surge in new patients, especially young children under five, in the United States.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOXZOGO (Vosoritide) for Hypochondroplasia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical is strategically broadening VOXZOGO's (vosoritide) application beyond achondroplasia. The company anticipates completing enrollment for its crucial Phase 3 study in hypochondroplasia during the first half of 2025, with a potential market introduction slated for 2027. This expansion into a related genetic growth disorder is a key driver for VOXZOGO's projected sustained high growth trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVOXZOGO (Vosoritide) for Idiopathic Short Stature, Noonan Syndrome, Turner Syndrome, and SHOX Deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical's VOXZOGO (vosoritide) is a key player in their portfolio, particularly as they expand its reach for various growth-related conditions. The CANOPY clinical program is actively exploring VOXZOGO's efficacy in idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency. This strategic expansion aims to significantly broaden VOXZOGO's market potential by tackling a wider array of skeletal dysplasias.\u003c\/p\u003e\n\u003cp\u003eThis pipeline expansion is a clear indicator of BioMarin's commitment to leveraging VOXZOGO's established success. By targeting these additional indications, the company is not only diversifying its revenue streams but also solidifying its position as a leader in rare genetic diseases. The market for treatments addressing short stature and related conditions is substantial, and VOXZOGO's potential to address multiple unmet needs positions it favorably within BioMarin's BCG matrix, likely as a star or question mark depending on the stage of development and market penetration in these new areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePALYNZIQ (Pegvaliase) for Phenylketonuria (PKU) in Adolescents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePALYNZIQ, a treatment for phenylketonuria (PKU), has demonstrated robust performance, with revenue experiencing double-digit growth throughout 2024. This upward trajectory is projected to persist into 2025, indicating sustained market demand.\u003c\/p\u003e\n\u003cp\u003eThe upcoming mid-2025 release of Phase 3 study results for adolescents aged 12-17 is a critical development. These findings are expected to be instrumental in supporting regulatory submissions for expanded age indications in both the United States and Europe during the latter half of 2025.\u003c\/p\u003e\n\u003cp\u003eThis potential label expansion is poised to significantly enhance PALYNZIQ's market penetration and drive further revenue growth, solidifying its position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePALYNZIQ's 2024 revenue saw double-digit increases.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eContinued growth is anticipated for 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePhase 3 adolescent data (ages 12-17) expected mid-2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential U.S. and European label expansions in H2 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMN 351 for Duchenne Muscular Dystrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBMN 351 is BioMarin Pharmaceutical's next-generation oligonucleotide therapy targeting Duchenne Muscular Dystrophy (DMD). This innovative treatment aims to address a severe rare disease with substantial unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eInitial proof-of-concept data for BMN 351 is anticipated in the latter half of 2025. This data will include crucial information on muscle dystrophin levels after 25 weeks of patient dosing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBMN 351: \u003c\/strong\u003eA promising pipeline candidate for Duchenne Muscular Dystrophy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDMD Market: \u003c\/strong\u003eA severe rare disease with significant unmet medical need, indicating high growth potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Data Point: \u003c\/strong\u003eExpected muscle dystrophin levels after 25 weeks of dosing in H2 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBioMarin's Strategy: \u003c\/strong\u003eFocus on developing advanced therapies for rare genetic disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin's Blockbusters: VOXZOGO \u0026amp; PALYNZIQ Soar!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVOXZOGO is BioMarin's leading star, demonstrating exceptional growth and market penetration. Its revenue surged to $735 million in 2024, a 56% increase year-over-year, with projections for 2025 between $900 million and $950 million.\u003c\/p\u003e\n\u003cp\u003eThe drug's expansion into hypochondroplasia, with Phase 3 enrollment completion expected in H1 2025 and a potential 2027 market introduction, further solidifies its star status. Ongoing trials for idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency also highlight VOXZOGO's potential to capture significant market share in related genetic growth disorders.\u003c\/p\u003e\n\u003cp\u003ePALYNZIQ also shines as a star, achieving double-digit revenue growth in 2024 and expecting continued momentum into 2025. The anticipated mid-2025 release of Phase 3 adolescent data is crucial for potential label expansions in the US and Europe by H2 2025, which will likely boost its market presence and revenue further.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eBCG Category\u003c\/th\u003e\n\u003cth\u003e2024 Revenue\u003c\/th\u003e\n\u003cth\u003e2025 Projected Revenue\u003c\/th\u003e\n\u003cth\u003eKey Developments\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVOXZOGO\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e$735 million\u003c\/td\u003e\n\u003ctd\u003e$900 - $950 million\u003c\/td\u003e\n\u003ctd\u003eExpansion into hypochondroplasia (potential 2027 launch), ongoing trials for other growth disorders.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePALYNZIQ\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eDouble-digit growth\u003c\/td\u003e\n\u003ctd\u003eContinued growth\u003c\/td\u003e\n\u003ctd\u003ePhase 3 adolescent data mid-2025, potential US\/EU label expansion H2 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBioMarin's BCG Matrix analysis categorizes its rare disease treatments, guiding investment decisions for growth and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBioMarin's BCG Matrix offers a clear, actionable framework for prioritizing rare disease drug development.\u003c\/p\u003e\n\u003cp\u003eThis visual tool simplifies complex portfolios, enabling strategic resource allocation for maximum impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIMIZIM (Elosulfase Alfa)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVIMIZIM, an enzyme replacement therapy for Morquio A syndrome, is a key component of BioMarin Pharmaceutical's Enzyme Therapies segment. This portfolio experienced robust growth, expanding by 27% in the third quarter of 2024, indicating strong and consistent demand for BioMarin's rare disease treatments.\u003c\/p\u003e\n\u003cp\u003eAs an established therapy within a niche market, VIMIZIM likely contributes a stable and predictable cash flow to BioMarin. While specific 2024 growth figures for VIMIZIM alone are not publicly detailed, its role within the high-performing enzyme therapies division positions it as a valuable cash cow for the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNAGLAZYME (Galsulfase)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNAGLAZYME, featuring galsulfase, stands as a significant contributor within BioMarin Pharmaceutical's Enzyme Therapies segment. This product plays a crucial role in the company's financial landscape.\u003c\/p\u003e\n\u003cp\u003eIn the fourth quarter of 2024, NAGLAZYME experienced a revenue increase, bolstering the 9% overall growth seen in BioMarin's enzyme therapies division when compared to the fourth quarter of 2023. This consistent revenue generation highlights its status.\u003c\/p\u003e\n\u003cp\u003eThe established market for Mucopolysaccharidosis VI (MPS VI), for which NAGLAZYME is a treatment, underpins its strong cash-generating capabilities. Its reliable performance solidifies its position as a cash cow for BioMarin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALDURAZYME (Laronidase)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALDURAZYME, a vital enzyme replacement therapy for mucopolysaccharidosis I developed in partnership with Sanofi, demonstrated robust financial performance in 2024. The drug achieved an impressive 40% year-over-year revenue increase, largely influenced by strategic order timing that bolstered its financial contribution.\u003c\/p\u003e\n\u003cp\u003eThis significant growth underscores ALDURAZYME's position as a reliable revenue stream within BioMarin's enzyme therapies segment. Its consistent demand and strong sales figures solidify its status as a cash cow, providing stable financial backing for the company's broader research and development initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRINEURA (Cerliponase Alfa)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBRINEURA, a key product within BioMarin Pharmaceutical's Enzyme Therapies portfolio, is positioned as a cash cow. This segment experienced robust growth, with a 9% increase in the fourth quarter of 2024 and a sustained 8% growth in the first quarter of 2025. \u003c\/p\u003e\n\u003cp\u003eBRINEURA's consistent contribution to this expanding market segment underscores its role as a reliable revenue generator for BioMarin. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eBRINEURA contributes to BioMarin's Enzyme Therapies portfolio.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe Enzyme Therapies segment grew 9% in Q4 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe segment continued its growth with an 8% increase in Q1 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBRINEURA's performance solidifies its cash cow status.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePALYNZIQ (Pegvaliase) for Phenylketonuria (PKU) in Adults\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePALYNZIQ (pegvaliase) for phenylketonuria (PKU) in adults is a prime example of a cash cow for BioMarin Pharmaceutical. Its consistent demand and impressive double-digit revenue growth, observed throughout 2024, highlight its established position in a mature market.\u003c\/p\u003e\n\u003cp\u003eThis product is a significant cash generator, providing the financial resources necessary to fuel BioMarin's investments in other areas, such as research and development for new therapies. For instance, in the first quarter of 2024, PALYNZIQ contributed substantially to BioMarin's overall revenue, demonstrating its reliable financial performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePALYNZIQ's robust revenue growth in 2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIts role as a major cash flow contributor\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe product's established presence in the adult PKU market\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIts strategic importance in funding BioMarin's pipeline\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Cows Fueling Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin's established therapies, like VIMIZIM and NAGLAZYME, are key cash cows. The Enzyme Therapies segment saw a 27% expansion in Q3 2024, with NAGLAZYME specifically contributing to a 9% growth in that segment in Q4 2024. ALDURAZYME also demonstrated strong performance with a 40% revenue increase in 2024, solidifying these products as reliable revenue generators.\u003c\/p\u003e\n\u003cp\u003eBRINEURA, another significant product in the Enzyme Therapies portfolio, is also classified as a cash cow. This segment experienced a 9% growth in Q4 2024 and an 8% increase in Q1 2025, with BRINEURA's consistent performance underpinning its cash cow status.\u003c\/p\u003e\n\u003cp\u003ePALYNZIQ, a treatment for adult phenylketonuria, represents a strong cash cow due to its consistent demand and double-digit revenue growth throughout 2024. This product's substantial contribution in Q1 2024 highlights its importance in funding BioMarin's research and development initiatives.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapy Area\u003c\/th\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Performance Highlight\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIMIZIM\u003c\/td\u003e\n\u003ctd\u003eMorquio A syndrome\u003c\/td\u003e\n\u003ctd\u003eEnzyme Therapies\u003c\/td\u003e\n\u003ctd\u003ePart of 27% Q3 2024 growth\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAGLAZYME\u003c\/td\u003e\n\u003ctd\u003eMucopolysaccharidosis VI (MPS VI)\u003c\/td\u003e\n\u003ctd\u003eEnzyme Therapies\u003c\/td\u003e\n\u003ctd\u003eContributed to 9% Q4 2024 segment growth\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALDURAZYME\u003c\/td\u003e\n\u003ctd\u003eMucopolysaccharidosis I\u003c\/td\u003e\n\u003ctd\u003eEnzyme Therapies\u003c\/td\u003e\n\u003ctd\u003e40% year-over-year revenue increase in 2024\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRINEURA\u003c\/td\u003e\n\u003ctd\u003eRare genetic neurological disease\u003c\/td\u003e\n\u003ctd\u003eEnzyme Therapies\u003c\/td\u003e\n\u003ctd\u003ePart of 9% Q4 2024 and 8% Q1 2025 segment growth\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePALYNZIQ\u003c\/td\u003e\n\u003ctd\u003ePhenylketonuria (PKU) in adults\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eDouble-digit revenue growth in 2024\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eBioMarin Pharmaceutical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BioMarin Pharmaceutical BCG Matrix preview you are viewing is the exact, fully formatted document you will receive immediately after purchase. This comprehensive report, meticulously prepared by industry experts, offers a clear strategic overview of BioMarin's product portfolio, without any watermarks or demo content. You can confidently use this preview as a representation of the high-quality, analysis-ready file that will be yours to download and implement in your business planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610787463545,"sku":"biomarin-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomarin-bcg-matrix.png?v=1754746231","url":"https:\/\/growthsharematrix.com\/products\/biomarin-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}